| Field | Specification |
|---|---|
| Target | |
| Alternative names | PRO95780, anti-DR5, rhuMAb DR5 |
| UniProt # | |
| CAS no. | |
| Reactivity | |
| Applications | |
| Assay type | |
| Sample type(s) | Plasma, Serum |
| Sensitivity | |
| Detection range | |
| Detection method | |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Assay Principle
This microplate immunoassay quantifies Drozitumab by colorimetric detection: samples and kit standards are processed in parallel, and absorbance values are converted to concentrations through the per-plate standard curve.
Background
Drozitumab is a human monoclonal antibody directed against tumor necrosis factor receptor superfamily member 10B (TNFRSF10B), a member of tumor necrosis factor related apoptosis-inducing ligand (TRAIL). It was developed by Genentech as a drug for the treatment of cancers. This drug has been investigating in various trials for treating cancers including chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer. The efficacy and selectivity of drozitumab in rhabdomyosarcoma (RMS) has been evaluated in preclinical models. And results showed that drozitumab is effective, in vitro, against the majority of RMS cell lines that express caspase-8 and, in vivo, may provide long-term control of RMS. In preclinical glioblastoma models, drozitumab has been found to induce apoptosis and colony formation in several glioblastoma cell lines combined with BV6 (combination index<0.1). A study about triple-negative breast cancer reported that drozitumab could induce apoptosis in mesenchymal TNBC cell lines but not in cell lines from other breast cancer subtypes. The previous study about the treatment of pancreatic ductal adenocarcinoma has revealed that drozitumab could selectively eliminate CSCs, resulting in tumor growth inhibition and even regression of pancreatic tumors.
Specifications
| Assay Type | Quantitative Colorimetric ELISA |
|---|---|
| Detection Method | Colorimetric |
| Plate Format | 96-well (96T) |
| Sample Types | Plasma, Serum |
| Sensitivity | 0.156 μg/mL |
| Detection Range | 0.31-5 μg/mL |
| Recovery | 80-120% |
| Stability & Storage | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
| Shipping | 2-8 °C |
| CAS Number | 912628-39-8 |
| UniProt | O14763 |
| Alternative Names | PRO95780, anti-DR5, rhuMAb DR5 |
Performance Data
Performance is defined by a quantitative range of 0.31-5 μg/mL, an analytical sensitivity of 0.156 μg/mL, typical spike recovery of 80-120%. For best precision, target the central portion of the curve and confirm matrix behavior with spike-recovery and dilution-linearity checks before routine runs.
Target Notes
The target is also referenced in the literature as PRO95780, anti-DR5, rhuMAb DR5. Curated target information is available under UniProt accession O14763. The corresponding compound is registered under CAS 912628-39-8.
Common Research Applications
- Pharmacokinetic profiling of the drug in preclinical and translational research models
- Bioanalytical method development, bridging, and comparability studies
- Stability and formulation studies requiring reproducible concentration readouts
Safety & Handling
For Research Use Only. Not for diagnostic or therapeutic use. Handle all reagents and samples according to your institution's laboratory safety guidelines, and store components as recommended to preserve assay performance.
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.